# Long-Term Safety, Efficacy, and Durability of EN3835 in the Treatment and Retreatment of Plantar Fibromatosis

> **NCT05254457** · PHASE3 · COMPLETED · sponsor: **Endo Pharmaceuticals** · enrollment: 145 (actual)

## Conditions studied

- Plantar Fibromatosis

## Interventions

- **BIOLOGICAL:** EN3835

## Key facts

- **NCT ID:** NCT05254457
- **Lead sponsor:** Endo Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-02-14
- **Primary completion:** 2024-03-21
- **Final completion:** 2024-03-21
- **Target enrollment:** 145 (ACTUAL)
- **Last updated:** 2025-03-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05254457

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05254457, "Long-Term Safety, Efficacy, and Durability of EN3835 in the Treatment and Retreatment of Plantar Fibromatosis". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT05254457. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*